← Eichor
Study identifier: NCT07296705 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC

Condition: Muscle Invasive Bladder Cancer (MIBC)  ·  Sponsor: Fujian Medical University Union Hospital

PhasePhase 2
Planned participants25
Who can joinAll sexes, 18 Years to 85 Years
Healthy volunteersNo

About this study

This is a multicenter, open-label, prospective, single-arm, phase II study designed to evaluate the efficacy and safety of neoadjuvant zanidatamab combined with tislelizumab and chemotherapy, followed by selective bladder preservation, in patients with HER2-positive muscle-invasive bladder cancer (MIBC) staged cT2-4aN0-1M0.

This description comes directly from the study's public registry record.

Talk to the study team

Shaoxing Zhu, MD  ·  86-18758872716  ·  zsx2005@126.com

Always discuss trial participation with your own doctor first.

Locations (12)

Fujian Medical University Union HospitalFuzhou, Fujian, ChinaRecruiting
Fujian Provincial Hospital Affiliated to Fuzhou UniversityFuzhou, Fujian, ChinaRecruiting
Affiliated Hospital of Putian UniversityPutian, Fujian, ChinaRecruiting
Quanzhou First Hospital Affiliated to Fujian Medical UniversityQuanzhou, Fujian, ChinaRecruiting
Sanming First HospitalSanming, Fujian, ChinaRecruiting
The First Affi liated Hospital of Xiamen UniversityXiamen, Fujian, ChinaRecruiting
Zhangzhou Affiliated Hospital to Fujian Medical UniversityZhangzhou, Fujian, ChinaRecruiting
Jiangxi Cancer HospitalNanchang, Jiangxi, ChinaRecruiting
Shandong Cancer HospitalJinan, Shandong, ChinaRecruiting
Fudan University Shanghai Cancer CenterShanghai, Shanghai Municipality, ChinaRecruiting
Zhejiang Cancer HospitalHangzhou, Zhejiang, ChinaRecruiting
The First Affiliated Hospital of Wenzhou Medical UniversityWenzhou, Zhejiang, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07296705